Dibutylstannane


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
1050 CEBPA Increases expression PMID:29787037
1536 CYBB Increases expression PMID:24631921
1583 CYP11A1 Decreases activity PMID:33862173
1583 CYP11A1 Decreases expression PMID:33862173
1588 CYP19A1 Decreases activity PMID:11751016
1975 EIF4B Increases expression PMID:36372856
2167 FABP4 Increases expression PMID:29787037
2516 NR5A1 Decreases expression PMID:33862173
3283 HSD3B1 Decreases activity PMID:33862173
3283 HSD3B1 Decreases expression PMID:33862173
3291 HSD11B2 Decreases activity PMID:22796344
3569 IL6 Increases expression PMID:24631921
3973 LHCGR Decreases expression PMID:33862173
4023 LPL Increases expression PMID:29787037
4842 NOS1 Decreases activity PMID:15464999
4843 NOS2 Increases expression PMID:24631921
5468 PPARG Increases expression PMID:29787037
5894 RAF1 Decreases expression PMID:24038145
6194 RPS6 Affects expression PMID:36372856
6256 RXRA Increases expression PMID:29787037
63924 CIDEC Increases expression PMID:29787037
6770 STAR Decreases expression PMID:33862173
7124 TNF Increases expression PMID:24631921

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.